Breaking News, Financial News

Financial Report: Johnson & Johnson

Johnson & Johnson
 
3Q Revenues: $15 billion (+13%)

3Q Earnings: $2.5 billion (-8%)

YTD Revenues: $45.1 billion (+14%)

YTD Earnings: $8.2 billion (-8%)

Comments: Worldwide pharmaceutical sales were $6.1 billion in the quarter, up 4%. Growth reflects the strong performance of Topamax, Remicade, and antipsychotic franchise, which includes Risperdal, Risperdal Consta and Invega. Earnings for the quarter include an after-tax restructuring charge of $528 million associated with a cost improvement program.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters